#PharmaInsights #Retatrutide #Obesity #GLP1 #GIP #Glucagon #ObesityMedicine #ClinicalResearch #MedicalEducation #EvidenceBasedMedicine #PharmaceuticalMarketing To view or add a comment, sign in Recent clinical trial data on aleniglipron underscores three critical developments in obesity pharmacotherapy
Common Adverse Events The most common adverse events in Phase 2 trials were gastrointestinal in nature, reflecting the class effects of GLP-1 receptor activation on gastric motility and central appetite pathways
Product quality matters because peptide purity, sterility, labeling accuracy, and storage conditions can vary significantly
The high cost of GLP-1 drugs, used primarily for type 2 diabetes and obesity, are driven by from expensive R&D, complex manufacturing processes, and stringent quality control
Jiang X, Mak PY, Mu H, Mak D, Zhang Q, Konopleva M, Andreeff M , Carter BZ
Consistently, our group continues to review literature on the impact of plants like Camellia sinensis and Aspalathus linearis , including prominent bioactive compounds from some of these plants such as gallic acid and isoorientin for their ameliorative effects against metabolic complications (Dludla et al., 2019
